{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:59:30Z","timestamp":1760403570349,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.euroneuro.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T15:16:10Z","timestamp":1338304570000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs"],"prefix":"10.1016","volume":"23","author":[{"given":"Peter","family":"Manu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martien","family":"Wampers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud","family":"van Winkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"De Hert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2012.05.002_bib1","first-page":"2","article-title":"Guidelines for rating global assessment of functioning (GAF)","volume":"10","author":"Aas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2012.05.002_bib2","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1210\/jc.2010-1698","article-title":"Role of glycated hemoglobin in the prediction of future risk of T2DM","volume":"96","author":"Abdul-Ghani","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antiosychotic drugs and obesity and diabetes","volume":"65","author":"American Diabetes Association","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes \u2013 2010","volume":"33(suppl 1)","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.euroneuro.2012.05.002_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1464-5491.2007.02106.x","article-title":"HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review","volume":"24","author":"Bennett","year":"2007","journal-title":"Diabet Med."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.05.002_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1309\/AJCPJBG0WYRAHN0R","article-title":"Hemoglobin A1c testing alone does not sufficiently identify patients with prediabetes","volume":"135","author":"Bersoux","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jad.2009.10.023","article-title":"Weight gain, obesity and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)","volume":"124","author":"Bond","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/00365513.2010.547947","article-title":"The relationship between glycosylated haemoglobin (HbA1c) and measures of insulin resistance across a range of glucose tolerance","volume":"7","author":"Borai","year":"2011","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2337\/dc10-0644","article-title":"Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction: a 6-year community-based prospective study","volume":"34","author":"Choi","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.euroneuro.2012.05.002_bib11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1399-5618.2008.00625.x","article-title":"Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics","volume":"10","author":"Correll","year":"2008","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4088\/JCP.v69n0409","article-title":"Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single low-density lipoprotein cholesterol threshold or complex national standard?","volume":"69","author":"Correll","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.bp.110.084665","article-title":"A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia","volume":"199","author":"De Hert","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib15","first-page":"18","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-0179-2-14","article-title":"Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a crosssectional study","volume":"2","author":"De Hert","year":"2006","journal-title":"Clin. Pract. Epidemol. Ment. Health"},{"issue":"9","key":"10.1016\/j.euroneuro.2012.05.002_bib18","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s00125-009-1443-3","article-title":"Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?","volume":"52","author":"Faerch","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.metabol.2010.06.017","article-title":"Insufficient sensitivity of hemoglobin A1c determination in diagnosis or screening of early diabetic states","volume":"60","author":"Fajans","year":"2011","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib20","first-page":"408","article-title":"American Heart Association\/National heart, Lung and Blood Institute. Definition of metabolic syndrome","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(11)60472-8","article-title":"HbA1c 5.7\u20136.4% and impaired fasting plasma glucose for the diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study","volume":"378","author":"Heianza","year":"2011","journal-title":"Lancet"},{"issue":"1-2","key":"10.1016\/j.euroneuro.2012.05.002_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.20452\/pamw.877","article-title":"Hemoglobin A1c for the diagnosis of diabetes: practical considerations","volume":"120","author":"Herman","year":"2010","journal-title":"Pol. Arch. Med. Wewn"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.05.002_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2337\/dc10-1314","article-title":"Implications of alternative definitions of prediabetes for prevalence in U.S. adults","volume":"34","author":"James","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","article-title":"Treatment with antipsychotics and the risk of diabetes in clinical practice","volume":"197","author":"Kessing","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.numecd.2011.02.006","article-title":"The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go","volume":"21","author":"Lapolla","year":"2011","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.euroneuro.2012.05.002_bib26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/jcp.2009.065821","article-title":"Ethnic differences in glycated haemoglobin between white subjects and those of South Asian origin with normal glucose tolerance","volume":"63","author":"Likhari","year":"2010","journal-title":"J. Clin. Pathol."},{"issue":"7\u20138","key":"10.1016\/j.euroneuro.2012.05.002_bib27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuropharm.2006.07.006","article-title":"Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats","volume":"51","author":"Lin","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib28","first-page":"22","article-title":"Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c","author":"Lipska","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.euroneuro.2012.05.002_bib29","doi-asserted-by":"crossref","DOI":"10.2337\/dc10-0679","article-title":"A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors","volume":"33","author":"Lorenzo","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4088\/JCP.10m06822","article-title":"Prediabetes in patients treated with antipsychotic drugs","volume":"73","author":"Manu","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and and beta-cell function from fasting plasma glucose and insulin concentration in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib32","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a PRISMA Meta-analysis","author":"Mitchell","year":"2012","journal-title":"Schizophr. Bull"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2012.05.002_bib33","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.05.002_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1262-3636(07)70117-9","article-title":"Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes\u2014data from the National diabetes Register in Sweden","volume":"30","author":"Nilsson","year":"2004","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib36","first-page":"737","article-title":"HOMA-IR and related clinical parameters","volume":"55","author":"Notsu","year":"2007","journal-title":"Rinsho Biori"},{"issue":"10","key":"10.1016\/j.euroneuro.2012.05.002_bib38","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2337\/dc08-0577","article-title":"Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001\u20132004","volume":"31","author":"Pani","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.jcp.0000218407.10362.6e","article-title":"To what extent do the PANSS and CGI-S overlap?","volume":"26","author":"Rabinowitz","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10654-011-9619-9","article-title":"Prognostic value of hemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening","volume":"26","author":"Schottker","year":"2011","journal-title":"Eur. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.05.002_bib42","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc08-1699","article-title":"Elevagted A1C in adults without a history of diabetes in the U.S.","volume":"32","author":"Selvin","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2012.05.002_bib45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib46","article-title":"Usefulness of hemoglobin A1c as a criterion define the metabolic syndrome in a cohort of Italian nondiabetic white subjects","author":"Succurro","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"1-8","key":"10.1016\/j.euroneuro.2012.05.002_bib47","article-title":"The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature","volume":"10","author":"van der Zwaal","year":"2011","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new onset diabetes, within 3 months after initiation or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"van Winkel","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.05.002_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2337\/dc09-0677","article-title":"Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study","volume":"33","author":"van't Riet","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2012.05.002_bib50","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pds.1781","article-title":"The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study","volume":"18","author":"Yood","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:24Z","timestamp":1760377824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0924977X12001216"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.05.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}